Events & Trainings

Current meetings, workshops, education

Academic Events

As a specialist scientific organisation, we hold many challenging events every year.

In a two-year cycle, the AGAH holds an acclaimed scientific congress in Germany, where relevant topics that interest our members are discussed – alternating with a scientific event with one of our partner organisations, AHPPI in UK, Bapu in Belgium or Association Française de Pharmacologie Translationelle (AFPT) -Le Club Phase I in France.

In addition, scientific workshops are held on special topics and there is a yearly national discussion round together with the BfArM, where mostly safety-relevant matters in early-phase clinical studies are discussed. The programme is rounded off with training courses, entitled Introductory or Applied Workshops for young scientists and a training programme specifically for study nurses.

  • DETAILS

    AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

    Haus am Dom - Katholische Akademie Rabanus Maurus  |  Feb 24 - Feb 24, 2026  |  13:00 – 17:30

    in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

  • DETAILS

    AFPT - Club Phase 1 Course

    Partner-Event  |   |  Mar 9 - Mar 13, 2026

    Pre-Clinical and Clinical Safety in Early Development Human Trials” - by AFPT-Club Phase 1 & EUFEMED

  • DETAILS

    11th German Pharm-Tox Summit

    Partner-Event  |  Heinrich Heine University Düsseldorf  |  Mar 17 - Mar 20, 2026

    92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

  • DETAILS

    28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

    Leonardo Weimar  |  Apr 23 - Apr 25, 2026

    This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

  • DETAILS

    AGAH Workshop: Toxic Truths and Dosing Dilemmas

    SocraTec R&D Oberursel  |  May 7 - May 8, 2026  |  13:00 – 13:00

    Navigating Early Drug Development – Translational Aspects of CNS Safety Findings

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

    Digital Event  |  Oct 22 - Nov 6, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

  • DETAILS

    Introductory Course in Exploratory Medicines Development – Part II face2face

     |  Nov 24 - Nov 27, 2026

    This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

AGAH e.V.
AGAH Conference 2026

"Optimism, Courage, and Pragmatism – Human Pharmacology 2030"

Feb 24 - Feb 26, 2026
PROGRAMME

 SCHEDULE AT A GLANCE

Thuesday, 24th February 2026
Pre-Meeting Workshop | 13:00–17:30
"Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)"

AGAH Mitgliederversammlung/General Assembly | 19:00

Wednesday, 25th February 2026 | 09:00–18:00
Session 1 | Session 2 | Session 3
Conference Get-Together | 18:00–20:30

Thursday, 26th February 2026 | 07:30–14:00
AGAH Breakfast Session – Meet the Expert
Session 4 | Session 5 | Session 5
Concluding, Recap and Farewell

Download conference fees and programme PDF:

Registration Information

Early registration fees: until 31th October 2025


Registration Link:

Become a Sponsor and/or Exhibitor

We kindly invite you to support us as an exhibitor and/or sponsor to help making this significant event a success and enhance the experience for all participants. We offer a range of sponsorship and exhibition options, each accompanied by promotional benefits for your company. Please refer to the brochure for more details. Please request these from our Conferenc office: agah-meetings@csihamburg.de

By sponsoring this event, your Company will expand visibility among key opinion leaders in early-phase development, regulatory authorities, ethics committees, and industry professionals. This is an excellent opportunity to showcase your commitment to advancing innovative medicines and supporting state-of-the-art clinical research.


Thank you for the support, Status December 2025

ARENSIA Exploratory Medicine GmbH
Bayer Aktiengesellschaft
CELERION Switzerland
Dr. Falk Pharma GmbH
NUVISAN GmbH
Occams Coöperatie U.A.
SGS Belgium NV 
T-Systems International GmbH,T-Health
WuXi App Tec

CALL FOR ABSTRATCS – Deadline Extension until 17 November 2025

The Organizing Team of the AGAH Conference 2026 invites abstracts for poster presentation at the conference dealing with any of the following aspects of medicines development in humans.
• Model-Informed Drug Development – Progress and Outlook
• Dose Selection for Phase 2 and Phase 3 – Optimal and Optimus
• Overly Complex Early Phase Trials – Disruptive Proposals for Improvement
• Artificial Intelligence Impacting Clinical Pharmacology – A Dynamic Field of   Opportunities
• Regulatory Enablers of Innovative Early Medicines Development

The early registration fee will be reduced by 100 € if you present a poster at the Annual Conference. Please submit your abstract as a pdf using this template:

Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
AGAH Workshop | Physiology-Based Pharmacokinetic (PBPK) model application

in Model-Informed Drug Development (MIDD) -As part of the AGAH Conference. Can also be booked individually.-

Feb 24 - Feb 24, 2026  |  13:00 – 17:30
Program Information

Programme Draft by:

AGAH Conference

Registration Information

Early registration fees: until 31th October 2025

-As part of the AGAH Conference. Can also be booked individually.-

Event Location
Haus am Dom - Katholische Akademie Rabanus Maurus
Domplatz 3
AFPT - Club Phase 1 Course

Pre-Clinical and Clinical Safety in Early Development Human Trials” - by AFPT-Club Phase 1 & EUFEMED

Mar 9 - Mar 13, 2026
This course addresses

postgraduates in life sciences interested in early clinical development of medicinal products. The training of several days provides a concise overview on safety in Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man to proof-of-concept clinical trials.

https://courses.2mpact.be/afpt-course-2026

Registration Information

Member ticket             € 1,600.00
Non-member ticket     € 2,100.00

This event is organised by 2Mpact for AFPT - Club Phase 1.You need to create your account on their website in order to be able to register for this event.

Payments of a registration fee covers the cost to attend all courses, educational material, coffee breaks, and all lunches during the course. Notice that this registration fee does not cover transportation fee and accommodation fee.

Learning Outcomes:

On successful completion, students should be able to demonstrate an understanding / knowledge of the following:  

  •  Minimal nonclinical safety package to support the first dose in human (FIH)(Remember).
  •  Risk assessment from non-clinical safety package (Apply).
  •  How to read and understand an Investigator’s Brochure (IB) prior to early clinical trials (Apply).
  •  Contributing safety findings from early phase trial to the IB (Apply).
  •  Specific aspects of how-to set-up and conduct safe early phase clinical trials (Apply).
  • Selection of appropriate trial population (Understand).
  • Assessment, evaluation, and reporting of safety data from early clinical trials (Understand).
  • Defining pharmacokinetic (PK) endpoints / exposure limit for early phase clinical trials (Apply).
  • Safety biomarkers (Understand).
  • Development safety update reports (Apply).
  • Development of risk management plans (Apply).
  • Most important medical emergencies in early clinical trials (Remember).
  • Characteristic safety issues involved in the development of biologicals and advanced therapies (Understand).


Event Location
University Paris-Saclay
Event Manager
2Mpact for AFPT - Club Phase 1
11th German Pharm-Tox Summit

92. Jahrestagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT)

Mar 17 - Mar 20, 2026
Place your research on the stage

Welcome to the 11th German Pharm-Tox Summit 2026
in cooperation with
the Association for Applied Human Pharmacology (AGAH),
and the Dutch Society of Toxicology (NVT)

Join us in shaping the future of pharmacology and toxicology. Submit an abstract and take the opportunity to present your findings to the plenum. By submitting your abstract you become part of the scientific program and get the chance to share your scientific expertise with your colleagues!
All abstracts will be published as a supplement of "Naunyn-Schmiedeberg's Archives of Pharmacology" (Springer Verlag). 
Your contribution may be selected for a poster prize or a young investigator award.

Take your chance – Submit your abstracts by 1 October 2025!

https://gpts-kongress.de/program-abstracts/abstract-submission

Registration Information

Veranstalter

 •    German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
•    German Society for Pharmacology (DGP)
•    German Society for Toxicology (GT)
•    German Society for Clinical Pharmacology and Therapy (DGKliPha)


Tagungsleitung

Univ.-Prof. Dr. med. Maria Grandoch, M.Sc.
Prof. Dr. Jens W. Fischer
Prof. Dr. rer. nat. Gerhard Fritz

Fachgebiete

Pharmacology, clinical pharmacology and toxicology General Medical Research Food & Product Safety Pharmacy, Pharmaceutical/Bio/Medical Chemistry Biotechnology Environmental Medicine

Kongresssprache

Englisch

Additional Information
Event Location
Heinrich Heine University Düsseldorf
Building: 22.01,
Roy Lichtenstein,
40225 Düsseldorf
Event Manager
Conventus Congressmanagement & Marketing GmbH
28th Pharmacokinetics/Pharmacodynamics (PK/PD) Expert Meeting

This meeting will take place at Hotel Leonardo Weimar under the auspices of AGAH (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V.) and starts with a joint Dinner on 23 April 2026. The scientific programme begins on Friday morning, 24 April 2026 and ends on Saturday, 25 April 2026 at lunchtime.

Apr 23 - Apr 25, 2026
Program Information

Preliminary Programme Download:


Registration Information

Start you registration from 15 November 2025 - Book your seat in time - number of participants is limited.

The conference fee includes also the accommodation costs, further information is available within the registration.


PLEASE START YOUR

Awards

Young scientists: Hans Günter Schäfer Award
Generous donations have enabled the Organizing Committee of the PK/PD Expert Meeting to reward outstanding contributions to the PK/PD field by young scientists with the Hans Günter Schäfer Award (cash amount of 1.000 EUR plus free meeting participation incl. travel expenses) issued in memory of the original initiator of the PK/PD Expert Meeting. The award is kindly sponsored by the Frankfurt Foundation Quality of Medicines.
If you are a Doctorate student or young scientist (less than two years after PhD degree) and want to apply for this award, send your peer-reviewed, published manuscript as a pdf file to Tobias Pähler - tobias.paehler[@]sanofi.com. Manuscript submissions must be accompanied by a brief description (500 words maximum) of how your manuscript fits into the overall scientific context of the respective research area, with a specific focus on its innovation, methodology and clinical or in vivo relevance. Submission deadline: 1 February 2026; applicant notification by 10 March 2026. The winner will be announced on the website of the PK/PD Expert Meeting and will present their work as part of the main conference.

Master / Doctorate students: Best presentation award
Three young PK/PD scientists will be given the opportunity to give an oral presentation of their work (5 minutes) as part of the main conference. All invited presenters will participate free of charge (incl. accommodation). The best presenter will be honored and will receive the “Young Scientist Best Presentation Award” plus reimbursement of travel expenses.
If you are a Master thesis or Doctorate student and want to apply for this award, send an abstract (500 words maximum) to Tobias Pähler - tobias.paehler[@]sanofi.com.
Submission deadline: 1 February 2026; applicant notification by 10 March 2026.
Three applicants will be selected and invited for presentation.

Application to both awards is possible. However, expectation is that a dedicated abstract is written for the ‘Best presentation award’, submission of one complete manuscript for both categories will not be accepted.


General Terms of Registration

Event Location
Leonardo Weimar
Belvederer Allee 25,
99425 Weimar
AGAH Workshop: Toxic Truths and Dosing Dilemmas

Navigating Early Drug Development – Translational Aspects of CNS Safety Findings

May 7 - May 8, 2026  |  13:00 – 13:00
Program Information

AGAH Workshop on the Early Safety Assessment of Drugs

with a Focus on CNS Safety Findings – Concepts, Strategies, and Potential Pitfalls.

Developing drugs with CNS-related safety concerns poses distinct challenges. Robust strategies are essential to identify, characterize, and mitigate risks early in clinical development. This AGAH workshop offers a deep dive into translational aspects, risk management strategies, and real-world lessons - including insights that shaped the 2018 revision of the EMA first-in-human guideline, designed to critically evaluate and refine decision-making in early-phase trials. 


Key questions we will explore together:

1.    Which early safety assessment results are most robust from a translational perspective?

2.    What strategies best support human risk/benefit evaluation in drug development?

3.    How have regulatory guidelines evolved to strengthen risk mitigation in first-in-human studies?


Real-world case studies – including both discontinued compounds (e.g., BIA 10-2474) and approved drugs – will illustrate these key questions. While the focus is on CNS-active compounds, the principles and strategies explored in this workshop are broadly applicable across therapeutic areas.


Preliminary schedule

Thursday: 13:00–19:00
Friday: 8:30 –13:00

Registration Information

Participation fee

750 € Regular
500 € Member* 
500 € Junior Scientist up to the age of 30
250 € Member of Regulatory Agencies or ethics committees

*of the following EUFEMED society: AGAH, AHPPI, AFPT - Le Club Phase 1, HEALIXIA, POLFEMED

START YOUR:

Event Location
SocraTec R&D Oberursel
Im Setzling 35,
61440 Oberursel
Introductory Course in Exploratory Medicines Development – Part I online (6 half-days)

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Oct 22 - Nov 6, 2026
Program Information

Learning Outcomes

On successful completion of Part 1, students should be able to demonstrate an understanding / knowledge of the following:

  • principal steps in drug development - from compound selection to marketing application and beyond
  • pertinent issues involved in the undertaking of early clinical research
  •  specific aspects of how to set-up and conduct early phase clinical trials
  •  regulation of medicines in Europe
  • development and review of compound-specific information to ensure adherence to scientific, medical, ethical, and legal provisions
  • integration of pertinent available scientific information into an IB and a clinical trial protocol
  • principles of trial design, protocol submission and clinical conduct
  • selection of appropriate trial population
  • most common early phase clinical trials and their specific requirements
  • assessment and evaluation of safety data from clinical trials
  • relevance of formulation properties and in vitro characteristics of the trial medication for design and planning of an early phase clinical trial
  • basics of pharmacokinetics
  • defining pharmacokinetic (PK) endpoints for early phase clinical trials
  • method validation according to good clinical (GCP) and good laboratory (GLP) practise practical aspects of bioequivalence trials
Registration Information

to follow

Part I - Online

Day 1    22 October 2026 13:00–18:00

Day 2    23 October 2026 13:00–17:00

Day 3    29 October 2026 13:00–18:00

Day 4    30 October 2026 13:00–17:00

Day 5     5 November 2026 13:00–18:00

Day 6     6 November 2026 13:00–17:00

Introductory Course in Exploratory Medicines Development – Part II face2face

This course addresses postgraduates in life sciences interested in early clinical development of medicinal products. Two training parts of several days provide a concise overview on Human Pharmacology / Translational Medicine spanning from non-clinical pharmacology and toxicology over first-in-man studies to proof-of-concept clinical trials.

Nov 24 - Nov 27, 2026
Program Information

Learning Outcomes

On successful completion of Part 2, students should be able to demonstrate an understanding / knowledge of the following:

  • nonclinical pharmacology and toxicology
  • molecular basis of drug actions
  • allometric scaling and dose proportionality assessments based on characteristic PK data
  • defining pharmacodynamic (PD) endpoints and biomarkers
  • differentiating between primary and secondary PK and PD endpoints
  • How to design an early clinical pharmacology developmant plan
  • planning and management of a first-in-man trial
  • principles of data management and information flow
  • principles of reporting and publication
  • principles of medical statistics
  • characteristic issues involved in the development of biologicals and biosimilars

This AGAH course meets the standards for high-quality postgraduate education and training in Medicines Development established by PharmaTrain and has been awarded a PharmaTrain Recognition. The previous courses  were accredited 3 ECTS (Parts I plus II)

Registration Information

to follow

Additional Information

Day 1     24 November 2026, 09:00–18:30

Day 2     25 November 2026, 09:00–18:00

Day 3     26 November 2026, 09:00–17:45

Day 4     27 November 2026, 09:00–15:00

Mandatory Test (conducted online)

                  1 December 2026, 17:00–19:00

Event Location
Oberursel (Germany)

Full commitment for our members

Our office is committed to working for our tasks and our members. You can reach us during normal office hours by phone or, of course, at any time by e-mail.

We will be happy to answer any questions you may have.

The Association for Applied Human Pharmacology (AGAH e.V.)

Association for Applied Human Pharmacology (AGAH)
Arbeitsgemeinschaft für Angewandte Humanpharmakologie e.V.

Sekretariat/Mitgliederverwaltung

Adress: Goernestraße 30
20249 Hamburg

Einstellungen zur Barrierefreiheit

Weitere Informationen zu unseren Maßnahmen zur Verbesserung der Barrierefreiheit finden Sie in der Erklärung zur Barrierefreiheit .